To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04666688
Title LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors PureTech
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
UCLA Los Angeles California 90095 United States Details
University of Colorado Hospital Denver Colorado 80045 United States Details
Sarah Cannon Research Institute at Health One Denver Colorado 80218 United States Details
Sarah Cannon Research Institute, Florida Cancer Specialists Sarasota Florida 34232 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
South Texas Accelerated Research Therapeutics Grand Rapids Michigan 49546 United States Details
Columbia University New York New York 10027 United States Details
Memorial Sloan-Kettering Cancer Center New York New York 10065 United States Details
Sarah Cannon Research Institute, Tennessee Oncology Nashville Tennessee 37203 United States Details
University of Texas, M.D. Anderson Cancer Center Houston Texas 77030 United States Details
South Texas Accelerated Research Therapeutics San Antonio Texas 78229 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field